Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672721 | 0.77 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20670460 | 0.77 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14838870 | 0.76 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31704117 | 0.76 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7639694 | 0.74 | RIPK1 (0.59) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31065045 | 0.73 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL451378 | 0.73 | RIPK1 (0.50) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29460546 | 0.73 | RIPK1 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3199154 | 0.72 | RIPK1 (0.49) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL23389649 | 0.71 | RIPK1 (0.52) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119136795-A | Conjugates of small molecule immunopotentiators as adjuvants with enhanced efficacy and reduced toxicity of NFKB activators | 芝加哥大学 | 2024-12-13 | — | — | CN | disclosed |